Glycation End Products and Diabetic Complications: Mechanisms and Biochemical Interventions

Background: Advanced glycation end products (AGEs) are a heterogeneous group of bioactive molecules formed through non-enzymatic glycation of proteins, lipids, and nucleic acids, particularly under hyperglycemic conditions. In diabetes mellitus, chronic elevation of AGEs plays a pivotal role in the pathogenesis of microvascular and macrovascular complications by promoting oxidative stress, inflammation, and extracellular matrix remodeling. AGEs accumulate in tissues over time, exerting long-lasting detrimental effects on cellular function and structural integrity. Methods and Results: This review outlines the molecular mechanisms by which AGEs contribute to diabetic complications and evaluates current biochemical strategies aimed at mitigating their effects. AGEs exert their pathogenic influence through receptor-dependent (primarily via RAGE) and receptor-independent pathways, leading to activation of pro-inflammatory transcription factors such as NF-κB, upregulation of adhesion molecules, and endothelial dysfunction. Key diabetic complications linked to AGE accumulation include nephropathy, retinopathy, neuropathy, and atherosclerosis. Biochemical assays have identified AGEs such as Nε-(carboxymethyl)lysine (CML), pentosidine, and methylglyoxal as biomarkers of glyco-oxidative stress and disease progression. Therapeutic approaches to limit AGE burden include inhibitors of glycation (e.g., aminoguanidine), crosslink breakers (e.g., ALT-711), antioxidants, and lifestyle interventions aimed at reducing dietary AGE intake. Novel agents targeting RAGE-ligand interactions and intracellular detoxification pathways, such as glyoxalase system enhancement, are under preclinical and clinical investigation. Conclusion: AGEs are central mediators of diabetic tissue injury through multifaceted biochemical pathways involving oxidative stress, inflammation, and receptor-mediated signaling.